









STUDY PROTOCOL

REVISED **Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial [version 2; peer review: 1 approved with reservations]**

Peter Olupot-Olupot ^{1,2}, William Okiror^{1,2}, Hellen Mnjalla ³, Rita Muhindo ^{1,2}, Sophie Uyoga ³, Ayub Mpoya³, Thomas N Williams^{3,4}, Rob terHeine⁵, David M Burger⁵, Britta Urban⁶, Roisin Connon ⁷, Elizabeth C George⁷, Diana M Gibb⁷, A Sarah Walker⁷, Kathryn Maitland ^{3,4}

¹Mbale Clinical Research Institute, Pallisa Road, PO Box 291, Mbale, Uganda

²Busitema University Faculty of Health Sciences, Mbale Regional Referral Hospital, Mbale, Uganda

³KEMRI Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya

⁴Department of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College, London, UK

⁵Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands

⁶Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK

⁷MRC Clinical Trials Unit, University College London, Aviation House, 125 Kingsway, London, WC28 6NH, UK

V2 **First published:** 23 Jun 2021, **6:161**
<https://doi.org/10.12688/wellcomeopenres.16968.1>

Latest published: 10 Jan 2023, **6:161**
<https://doi.org/10.12688/wellcomeopenres.16968.2>

Abstract

Background: African children with severe malaria are susceptible to Gram-negative bacterial co-infection, largely non-typhoidal *Salmonellae*, leading to a substantially higher rates of in-hospital and post-discharge mortality than those without bacteraemia. Current evidence for treating co-infection is lacking, and there is no consensus on the dosage or length of treatment required. We therefore aimed to establish the appropriate dose of oral dispersible azithromycin as an antimicrobial treatment for children with severe malaria and to investigate whether antibiotics can be targeted to those at greatest risk of bacterial co-infection using clinical criteria alone or in combination with rapid diagnostic biomarker tests.

Methods: A Phase I/II open-label trial comparing three doses of azithromycin: 10, 15 and 20 mg/kg spanning the lowest to highest mg/kg doses previously demonstrated to be equally effective as parenteral treatment for other salmonellae infection. Children with the highest risk of bacterial infection will receive five days of

Open Peer Review

Approval Status ?

1

version 2

(revision)


10 Jan 2023

version 1

23 Jun 2021



view

1. **Stephen J. Rogerson** , University of Melbourne, Melbourne, Australia

Any reports and responses or comments on the article can be found at the end of the article.

azithromycin and followed for 90 days. We will generate relevant pharmacokinetic data by sparse sampling during dosing intervals. We will use population pharmacokinetic modelling to determine the optimal azithromycin dose in severe malaria and investigate azithromycin exposure to change in C-reactive protein, a putative marker of sepsis at 72 hours, and microbiological cure (seven-day), alone and as a composite with seven-day survival. We will also evaluate whether a combination of clinical, point-of-care diagnostic tests, and/or biomarkers can accurately identify the sub-group of severe malaria with culture-proven bacteraemia by comparison with a control cohort of children hospitalized with severe malaria at low risk of bacterial co-infection.

Discussion: We plan to study azithromycin because of its favourable microbiological spectrum, its inherent antimalarial and immunomodulatory properties and dosing and safety profile. This study will generate new data to inform the design and sample size for definitive Phase III trial evaluation.

Registration: [ISRCTN49726849](#) (27th October 2017).

Keywords

Severe Malaria, Bacterial infection, African Children, Antibiotics, azithromycin, Clinical Trial, Pharmacokinetics, Pharmacodynamics, Biomarkers



This article is included in the [KEMRI | Wellcome Trust gateway](#).

Corresponding author: Kathryn Maitland (k.maitland@imperial.ac.uk)

Author roles: **Olupot-Olupot P:** Conceptualization, Funding Acquisition, Investigation, Project Administration, Supervision, Writing – Review & Editing; **Okiror W:** Data Curation, Investigation, Writing – Review & Editing; **Mnjalla H:** Methodology, Project Administration, Writing – Review & Editing; **Muhindo R:** Data Curation, Investigation, Writing – Review & Editing; **Uyoga S:** Investigation, Methodology, Supervision, Validation; **Mpoya A:** Methodology, Project Administration; **Williams TN:** Funding Acquisition, Methodology, Resources, Writing – Review & Editing; **terHeine R:** Investigation, Methodology, Validation, Writing – Review & Editing; **Burger DM:** Funding Acquisition, Investigation, Methodology, Resources, Writing – Review & Editing; **Urban B:** Conceptualization, Methodology, Resources; **Connon R:** Formal Analysis, Software, Validation, Writing – Review & Editing; **George EC:** Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Supervision, Validation, Writing – Review & Editing; **Gibb DM:** Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing; **Walker AS:** Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Supervision, Writing – Review & Editing; **Maitland K:** Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Funded by UK Joint Global Health Trials scheme: Medical Research Council, Foreign Commonwealth and Department Office, Department of Health and Social Care through the National Institute for Health Research and Wellcome Trust (Grant Number MR/P021492). Authors DM Gibb, EC George, AS Walker and R Connon were supported by the Medical Research Council (MC_UU_12023/26). ASW is a National Institutes of Health Research (NIHR) Senior Investigator. The views expressed do not represent those of NIHR or the Department of Health. TN Williams is supported by a Senior Fellowship from Wellcome (202800). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2023 Olupot-Olupot P *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Olupot-Olupot P, Okiror W, Mnjalla H *et al.* **Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial [version 2; peer review: 1 approved with reservations]** Wellcome Open Research 2023, 6:161 <https://doi.org/10.12688/wellcomeopenres.16968.2>

First published: 23 Jun 2021, 6:161 <https://doi.org/10.12688/wellcomeopenres.16968.1>

REVISED Amendments from Version 1

Changes made to the document

- 1) We have made a minor edit to the abstract so that our aims are clearer '...and investigate the impact of different levels of azithromycin exposure on change in C-reactive protein (a putative marker of sepsis at 72 hours), as well as on microbiological cure alone and as a composite with survival at 7 days'.
- 2) Additional abbreviations were added since the list was not comprehensive
- 3) We have edited a very long sentence in the introduction to improve readability and so that the point we were making is now clearer.
- 4) Under the section covering other favourable properties of azithromycin We were asked to justify the statement that azithromycin half-life is such that it is likely to offer protection from bacteraemia for a month. We agreed that the referenced paper did not make this clearer about the specific claim so we have amended this.
- 5) The Study Figure had a footnote missing for the *. We have now clarified that the sampling in Day 1–5 inclusive in the footnote next the the *.
- 6) The first sentence of the Trial monitoring section has been edited to make more sense.
- 7) Under trial status we added the following 'The trial completed recruitment on 4th October 2021 and follow up on 4th January 2022. The clinical trial data and PKPD are currently being analysed'.

Any further responses from the reviewers can be found at the end of the article

Abbreviations

AQUAMAT: Artesunate versus Quinine in the treatment of severe falciparum Malaria in African children AUC24h: area under the curve at 24 hours; AVPU: alert, voice, pain, unresponsive: system of recording patient's level of consciousness; CRF: case report form; CRP: C-reactive protein; *E. coli*: *Escherichia coli*; ETAT: emergency triage assessment and treatment; FEAST: Fluid Expansion As a Supportive Therapy; GCP: Good Clinical Practice Hb: haemoglobin; IBI: invasive bacterial infection; ICREC: Imperial College Research Ethics Committee; KWTRP: KEMRI Wellcome Trust Research Programme; MIC: minimum inhibitory concentration MRRH: Mbale Regional Referral Hospital; MRRH-REC: Mbale Regional Referral Hospital Research Ethics Committee; MRC: Medical Research Council; NTS: non-typhoidal salmonella; PCT: procalcitonin; PD: pharmacodynamic; *P. falciparum* HRP2: *Plasmodium falciparum* histidine-rich protein 2; PK: pharmacokinetic; PKPD: pharmacokinetic-pharmacodynamic; RDT: rapid diagnostic test; TRACT: TRansfusion and Treatment strategies of severe Anaemia in African children Trial; WHO: World Health Organization.

Introduction

Plasmodium falciparum malaria remains to be a common cause of hospital admission in much of sub-Saharan Africa, and plays a substantial role in under five-year mortality¹. Strategies to control or prevent malaria (including vaccines) have so far

offered limited short-term protection. Over the past decade some African countries have either documented no decline², an increase in hospitalisations with severe *P. falciparum* malaria³ or a resurgence of severe malaria following a period of sustained control. Thus, prevention strategies alone in many parts of Africa will not adequately address the burden that malaria poses on health services, particularly in countries where transmission is high. Even with the best (evidence-based) antimalarial treatment artesunate, children in the Artesunate versus Quinine in the treatment of severe falciparum malaria in African children (AQUAMAT) trial had an overall mortality of 6–8.5%⁴. The trial population were selected pragmatically (defined by parasite-positivity and the admitting clinician's desire to use parenteral rather than oral antimalarials) for generalisability of the results. However, mortality in children with severe malaria would almost certainly be substantially higher outside a Good Clinical Practice (GCP)-run trial and outside selected centres with a strong track record of research; and with more stringent clinical criteria defining severe malaria⁵. Thus, there is substantial potential for clinical trials addressing the safety and efficacy of adjuvant supportive therapies to not only close existing gaps in the severe malaria treatment algorithm, but also substantially improve outcomes⁶.

Children with severe malaria and bacterial co-infection, largely due to enteric Gram-negative organisms with a predominance of non-typhoidal salmonella (NTS) species, have substantially higher rates of in-hospital and post-discharge mortality⁷. An estimated one third of all severe malaria deaths in African children are attributable to bacterial co-infection⁸. Current guidance and evidence for treating co-infection in children is lacking, and there is no consensus on the dosage or length of treatment required. Identifying which children genuinely have bacterial co-infection is practically impossible. The indiscriminate use of antibiotics is both financially costly and may perpetuate the rise of antibiotic resistance. Establishing which children with malaria are at greatest risk of bacteraemia is critical to pragmatically inform a policy for targeted antibiotic therapy that could substantially reduce malaria-associated mortality while minimising the risks of excess antibiotic prescribing.

Bacterial co-Infection in severe malaria

We conducted a systematic review in 2013 examining studies among children with malaria admitted to hospitals or outpatient clinics in sub-Saharan Africa reporting invasive bacterial infection (IBI)⁹. We identified a total of 25 studies across 11 African countries which fulfilled the inclusion criteria. These comprised of 20 cohort analyses, two randomised controlled trials and three prospective epidemiological studies. We initially compared the prevalence of IBI in 20,889 children who were hospitalised with all-severity malaria to 27,641 children hospitalised with a non-malarial febrile illness. The mean prevalence of IBI was 5.58 (95% CI 5.5 to 5.66%) in children with malaria and 7.77% (95% CI 7.72 to 7.83%) in non-malaria illness. In the meta-analysis involving 10 studies (n=7,208) of children with severe malaria the mean prevalence of IBI was 6.4% (95% confidence interval (CI) 5.81 to 6.98%). Ten of the 25 studies reported mortality stratified by bacterial infection status. Case fatality was higher at 81 of 336, 24.1% (95% CI 18.9 to 29.4) in children with malaria/IBI co-infection compared to 585 of

5,760, 10.2% (95% CI 9.3 to 10.98) with malaria alone. In seven of 14 hospital studies, NTS was the commonest isolate and one other study listed enteric Gram-negative organisms as the most common isolates in malaria-infected children⁹. Thus, enteric Gram-negative organisms, and NTS in particular, cause the vast majority of bacteraemia co-infections⁹. Moreover, the poor sensitivity of blood cultures (due to low blood volumes in children and previous antibiotic use) means that the true prevalence of bacteraemia co-infection is likely to be significantly higher and 'nosocomial bacteraemia' will be acquired in a further 2–3.5% of children receiving a transfusion (commonly prescribed in severe malaria) due to poor quality.

Current management recommendations

Current recommendations indicate that antibiotics should be given to 'all children with suspected severe malaria in areas of moderate and high transmission until a bacterial infection is excluded... and should be based on culture and sensitivity results or, if not available, local antibiotic sensitivity patterns'¹⁰. However, many hospitals in Africa lack culture facilities or access to such data; thus, best practice is not obvious. In one study almost 50% of bacterial isolates were resistant to the antibiotics most commonly recommended (chloramphenicol and gentamicin for empirical use)¹¹. In the specific case of NTS, the efficacy of gentamicin is doubtful and susceptibility testing unreliable due to this infection's intracellular nature. For newer and broad-spectrum antimicrobials, apart from financial considerations, there are concerns that over-use could lead to resistance. A systematic review of studies and trials of supportive therapy in severe malaria was undertaken. Whilst definitive evidence for parenteral antimalarial treatment has now been provided^{4,10}, progress on supportive therapeutics has been limited. To date, of the 34 clinical trials involving adjunctive therapies in severe malaria, including 20 (59%) in African children, none of these trials have targeted bacterial co-infection⁶. Searching ClinicalTrials.gov and ISRCTN we found no trials addressing anti-microbial treatment of bacterial co-infection in severe malaria.

Justification for azithromycin for malarial sepsis

There are several reasons why we consider that azithromycin represents an attractive option in such an approach. Given the worldwide threat of antimicrobial resistance, the underlying principle is to test the narrowest spectrum antibiotic that would be practical, generalisable and plausibly have reasonable efficacy. There are several reasons for selecting azithromycin as the targeted antimicrobial intervention. Primarily, it is active against NTS, the commonest cause of bacterial co-infection in severe malaria⁹, against which currently recommended antimicrobials are ineffective (e.g. chloramphenicol, ampicillin/gentamicin combination)¹¹. It is also active against a range of other gram-negative and gram-positive organisms, although it is less active against *Escherichia coli* and *Klebsiella* spp. The alternative (effective) antimicrobial therapies we considered, given that they would likely be active against NTS¹², were, first, a full course (~seven days) of parenteral third generation cephalosporins. This has feasibility concerns as it would prolong hospital stay (median four-five days), and would be difficult (and potentially unethical) to blind. In contrast to macrolides, which are not widely used in other childhood diseases¹³, adding a major new indication for third-generation cephalosporins (severe malaria) also risks widening their use even further, and thus increasing

the threat of antimicrobial resistance to a second-line antibiotic recommended for other common childhood diseases. Quinolones (e.g. ciprofloxacin) are another alternative strategy, given their superior antimicrobial activity against *Salmonella* species¹³, *E. coli* and *Klebsiella* spp. However, resistance is generated through single mutations in the housekeeping genes *gyrA* or *gyrB*; and can be detected shortly after administration in healthy volunteer studies, suggesting resistant variants are commonly present at low levels or easily acquired¹⁴. A recent study found pathogenic ciprofloxacin-resistant *E. coli* were highly prevalent in healthy children and their mothers¹⁵, raising the possibility that widespread use in children with severe malaria without evidence of bacterial infection could have serious unintended consequences. Moreover, in most countries the use of fluoroquinolones in children is relatively contraindicated (due to concerns over musculoskeletal side-effects) except for use in multi-drug resistant infections where there are no suitable alternatives¹³. Finally, although cephalosporin and quinolone resistance rates are currently relatively low in relevant organisms in some African countries¹², they are much higher in Asia¹³, limiting generalisability of the trial's findings worldwide.

Other favourable properties of azithromycin include:

1. It is licenced for use and has a good safety profile in children.
2. Azithromycin's pharmacokinetic (PK) properties include extensive tissue distribution, prolonged phagocyte concentrations, and a longer elimination half-life (~50hours) than other macrolides, thus enabling once-daily dosing (versus more frequent dosing required for clindamycin)¹⁶.
3. Its long half-life is also likely to protect children at increased risk of NTS bacteraemia following a malaria episode¹⁷.
4. An accumulating body of evidence indicates some macrolides have beneficial properties independent of their antimicrobial effects¹⁸. It is thus plausible that azithromycin may also have a beneficial effect on immune activation and gut inflammation.
5. A further consideration is that azithromycin is a weak anti-malarial¹⁹, and has proved effective in treating *P. falciparum* malaria in early phase trials when used in combination with faster-acting antimalarials.
6. Dispersible azithromycin is currently widely available at an affordable price, costing 0.40 euros per 100mg dose in an oral formulation. i.e. two-six Euros per five-day paediatric treatment course.

Target population

Current recommendations indicate that antibiotics should be given to 'all children with suspected severe malaria in areas of moderate and high transmission until a bacterial infection is excluded'¹⁰. However, WHO definitions of severe malaria are very broad, incorporating high parasitaemia as a single criterion, and are thus applicable to a large proportion of paediatric admissions in such regions, with a relatively overall low case fatality (1–2%)²⁰, who are unlikely to benefit from antimicrobial therapy as a group. For this study (and in a future trial) we aim to target antibiotics to children with the highest risk of bacterial

co-infection, meeting 'Teule' criteria¹¹: that is, with malaria (positive blood film or ParacheckTM rapid diagnostic test, RDT); temperature > 38°C or < 36°C; and ≥ 1 of prostration, respiratory distress, haemoglobin (Hb) <5g/dl or HIV. These criteria identified 85% of bacterial co-infections, with a three-fold higher mortality than children admitted with malaria without these criteria.

Credibility: can antibiotics be targeted?

A major legitimate concern is whether future management guidelines can be implemented which try to reduce the overuse of antibiotics where microbiology services are poor or non-existent, thus an approach to targeting only those with IBI is not feasible in much of Africa. Within the context of this study and to inform a future trial, we aim to investigate approaches (that may be generalizable in future) to targeting antibiotics. We propose to use (i) simple clinical criteria: proposed by Nadjm *et al.*¹¹, the Teule criteria identifies 85% of malaria cases with culture-proven bacteraemia: a pathogen was isolated from 20% children meeting these criteria. Simple and objective criteria identifying those at risk would be more generalizable outside research centres and would be validated in this study. (ii) Potential biomarkers: even when quality-controlled blood-culture facilities are available, low sensitivity (due to frequent pre-hospital antibiotic therapy, low culture volumes from children and low bacterial density) and long times to culture-positivity (typically two-three days) mean that alternative approaches for identifying concurrent gram-negative bacteraemia would be highly valuable.

Protocol

Trial Registration [ISRCTN49726849](https://www.isrctn.com/ISRCTN49726849) (registered on 27th October 2017).

Protocol Version 1.2: Date 9th October 2018.

Justification for the study

This trial, designed to inform a key research gap, proposes targeted and appropriate antimicrobial treatment of children with severe malaria at greatest risk of bacterial co-infection. Incorporated in the design are experimental data to demonstrate that the mechanisms that azithromycin is targeting are biologically reasonable, that the dosing is providing the right exposure, and that there is a pharmacokinetic-pharmacodynamic (PKPD) link between azithromycin exposure and the potential mechanisms for reducing both short-term and microbiological cure (seven-day) and longer-term mortality (28-day). Comparison with a control group will also enable us to identify whether antimicrobial treatment can be further targeted.

At present pharmacological data are lacking on the correct dosage of oral azithromycin for treatment of bacterial co-infection in severe malaria in African children. We will therefore conduct a Phase I/II trial comparing three doses of azithromycin: 10, 15 and 20 mg/kg (prescribed for feasibility by weight-bands) spanning the lowest to highest mg/kg doses demonstrated to be equally effective as parenteral treatment for other salmonellae infection²¹.

Our hypotheses

1. Azithromycin given to children once-daily for five days in addition to standard treatment of severe malaria

(including anti-malarials) can provide adequate dosing in children admitted to hospital with severe malaria.

2. Children with severe malaria and culture-proven bacteraemia can be accurately identified using clinical criteria alone or in combination with a rapid diagnostic biomarker tests, in comparison with a control cohort of children hospitalized with severe malaria but not meeting Teule criteria, at low risk of bacterial co-infection.

Objectives

General objectives

Our principal objectives are to:

- (i) establish the appropriate dose of oral dispersible azithromycin as an antimicrobial treatment for children with severe malaria;
- (ii) investigate whether antibiotics can be targeted to those at greatest risk of bacterial co-infection using clinical criteria alone or in combination with a rapid diagnostic biomarker test.

Specific objectives

- (i) To conduct a Phase I/II trial comparing three doses of azithromycin: 10, 15 and 20 mg/kg (prescribed for feasibility by weight-bands) spanning the lowest to highest mg/kg doses demonstrated to be equally effective as parenteral treatment for other salmonellae infection.
- (ii) To determine, via PKPD modelling, the optimal azithromycin dose in severe malaria, and investigate associations between azithromycin exposure and pathogen susceptibility (minimum inhibitory concentration, MIC) with treatment outcome. Outcome measures will consist of changes in C-reactive protein (CRP), a putative marker of sepsis at 72 hours (continuous) and microbiological cure (seven-day) (binary), alone and as a composite with seven-day survival, while providing preliminary data on longer-term survival (to day 90).
- (iii) To evaluate whether a combination of clinical, point-of-care diagnostic tests, and/or biomarkers can accurately identify the sub-group of severe malaria with culture-proven bacteraemia by comparison with a control cohort of children hospitalized with severe malaria but not meeting Teule criteria, at low risk of bacterial co-infection.

Methods

Study site

The trial will be conducted in Mbale Regional Referral Hospital (MRRH), Eastern Uganda, where we already have an on-going collaborations^{22,23}, in an area with hyperendemic malaria and paediatric admissions of >20,000/year, approximately 50% with malaria parasitaemia. MRRH is now an established research hub of the KEMRI-Oxford-Wellcome Trust Major Overseas Programme, assisted by trial, data and laboratory management from Kilifi, Kenya.

Study design

A Phase I/II open-label trial comparing three doses of azithromycin: 10, 15 and 20 mg/kg (prescribed for feasibility by weight-bands) spanning the lowest to highest mg/kg doses demonstrated to be equally effective as parenteral treatment for other salmonellae infection.

Study populations

Children will be considered eligible for enrolment in this trial if they fulfil all the inclusion criteria and none of the exclusion criteria.

Inclusion criteria

Cases:

105 children aged six months to 12 years at admission to hospital with *P. falciparum* malaria (on either blood film or Paracheck™ RDT) and all of the following:

- i) Axillary temperature $>38^{\circ}\text{C}$ or $<36^{\circ}\text{C}$.
- ii) Teule severity criteria¹¹: any one of the following: prostration; respiratory distress; severe anaemia (haemoglobin $<5\text{g/dL}$) or HIV infection.
- iii) Parents willing/able to provide consent.

Controls

The control cohort of children (n=50) are those hospitalised with severe malaria but not meeting Teule criteria (i.e., low risk of bacterial co-infection) whose parents are willing/able to provide consent.

Exclusion criteria (cases only)

Major contraindications to azithromycin, e.g. strong existing clinical diagnosis of QT-prolongation. Concomitant use of interacting drugs: drugs that may cause QT-prolongation or drugs that may cause a pharmacokinetic interaction with azithromycin, like strong CYP3A/P-GP inducers and concomitantly administered antacids.

Sampling

Sample size determination

A formal sample size was not calculated. Phase I/II trials are an important step in the assessment of new or existing interventions providing the first data on the feasibility of using a product in a new application. They assess the effect of products (how well they work), and the side effects they may have. They are not usually designed to compare superiority of different products or interventions.

The aim is to generate pilot efficacy data on the optimal azithromycin dose for children with severe malaria, which will inform the design of a later larger Phase III trial. The numbers required to address the trial objectives are therefore balanced against the exposure of children in these settings to a therapeutic intervention (dose) for which there are limited data to date.

The overall sample size for the trial will be 105 children randomised 1:1:1 to receive 10, 15 or 20mg/kg azithromycin (based on weight-bands). This is sufficient for the PKPD sampling and modelling to determine an optimal dose in children with severe malaria using change in CRP at 72 hours, and microbiological cure (seven-day) alone and with seven-day survival. This is under the assumption that 20% of enrolled children (meeting Teule severity criteria) will have bacteraemia and that 80% of these infections will be caused by NTS or other enteric gram-negative organisms based on previous research.

Based on Monte Carlo simulations, we expect that all dose groups should reach the population reference target (adult) AUC_{24h} of at least $3.4\text{ h}\cdot\text{mg/L}$ ²⁴, although there are no data on

absorption in severe malaria, which is characterised by impaired gut function²⁵, hence the need for this pilot. Along with the 105 children with Teule criteria we will enrol 50 children meeting other inclusion criteria but without Teule criteria (and without any exclusion criteria) into the control group.

Study methods and procedures

Eligible children will be identified by the nurse and clinician on duty and registered in the eligibility screening log. A member of the trial team will then perform a rapid structured assessment of heart rate, oxygen saturation (pulse oximetry), respiratory rate, axillary temperature, blood pressure, markers of shock (capillary refill time, pulse volume and assessment of lower limb temperature) and severity (conscious level and respiratory distress). Children who are potentially eligible with suspected severe malaria will have a rapid bedside malaria test (detecting *P. falciparum* histidine-rich protein 2, HRP2) to determine malaria status and eligibility.

Randomisation procedure

Randomisation lists will be generated and kept at the Medical Research Council (MRC) Clinical Trials Unit at University College London, London. The randomisation envelopes will be prepared before the trial, using the lists at the Clinical Trials Facility, KEMRI Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya. These will be opaque and sealed and will contain a card with allocation. Children will be randomised (1:1:1) to receive 10, 15 or 20 mg/kg azithromycin (based on weight-bands). The cards will be numbered consecutively and opened in numerical order. Clinicians will be aware of the treatment-group dose assignments, but the laboratory tests are to be performed in a blinded manner.

Consent process

Once eligibility has been confirmed, authorised trial staff will approach parents/guardians to invite their child to take part in the trial. An information sheet will be provided to the parent/guardian in their usual language containing details of the TABS trial. The sheet will be read aloud to those who are unable to read. The doctor/nurse will check that the information has been fully understood and parents/guardians will be encouraged to ask questions they may have about their child's participation in TABS trial. The information sheet and consent includes details of the clinical trial, follow up and additional biological samples taken for the trial and permissions for sample storage. Where possible, prospective written informed consent will be sought from parents/guardians who will then be asked to sign the consent form. Consent will include permission for the collection of admission and follow-up blood samples for later aetiological investigations. If parents/guardians are unable to sign, a thumbprint will be taken in lieu of a signature. A copy of the consent form will be given to the parent/guardian, the original placed in the patient's medical notes, and a copy kept in the investigator site file. A number of children will present as emergencies where delay in study enrolment, and thus treatment, will not be practical or indeed humane. We will use a modified form of deferred consent; used in the FEAST trial²² and for which we have received ethical approval. It proposes to use a 'two-stage' consent process in this circumstance²⁶. Verbal assent will be sought from parents or guardians by the admitting medical team if it is considered that the full consent process would significantly delay treatment allocation and

consequently could be detrimental to the child’s health. Full consent will be sought once the child’s clinical condition has been stabilized. Caregivers will be provided with a brief verbal description of the trial and will be given the opportunity to “opt out”. As in the FEAST trial, if following an assent process a child died prior to full written consent, full consent would not be sought. This process of emergency consent was approved for FEAST and has been subsequently approved for use in a TRACT transfusion trial in Uganda and Blantyre²³.

Treatment allocation

Following consent, children will be randomly allocated to the treatment arms. Children, on admission to hospital with severe malaria (*see Inclusion criteria above*) eligible for the trial will be randomised to one of three doses of adjunctive once daily oral azithromycin doses, which will be given for five days in addition to a three-day course of parenteral artesunate. The comparator cohort with non-severe malaria will receive usual standard of care (oral artemisinin combination therapy). See Study Flow ([Figure 1](#)).




Figure 1. Trial flow. PK, pharmacokinetics; CRP, C-reactive protein. * Days 1-5 inclusive.

Pragmatic dosing chart

Rather than calculate azithromycin doses based on body weight (which in practice is poorly implemented), the trial will use weight bands (see [Table 1](#)) all using 100mg dispersible tablets, which are more practical and generalizable outside of clinical trials.

This weight-band dosing has been developed based on existing data²⁷ and will be validated by the nested PKPD sub-study (as has been done in several HIV trials). Children generally tolerate a wide range of azithromycin doses (5-20mg/kg); however, when given in combination with artesunate, doses of 20mg/kg more commonly resulted in vomiting (versus

artemether-lumefantrine)²⁸. Based on Monte Carlo simulations, we expect that all dose groups should reach the population reference target (adult) AUC_{24h} of at least 3.4 h*mg/L²⁴, although there are no data on absorption in severe malaria, which is characterised by impaired gut function²⁵, hence the need for this pilot.

Trial assessment schedule

Children will be intensively monitored during admission by the clinical team at least eight hourly in the first 72 hours following recruitment, and daily thereafter. Locator maps and contact numbers will be obtained to facilitate follow-up. All participants will then be seen at seven-days, 28-days and 90-days

Table 1. Pragmatic dosing chart for dispersible azithromycin.

| | 10 mg/kg | 100mg tabs | 15 mg/kg | 100mg tabs | 20 mg/kg | 100mg tabs |
|-------------|------------|------------|------------|------------|------------|------------|
| Weight (kg) | Weight x10 | Tab size | Weight x15 | Tab size | Weight x20 | Tab size |
| 5.5 - 6.4 | 55-64 | 0.5 | 82.5-97 | 1 | 110-129 | 1 |
| 6.5 - 7.4 | 65-74 | 0.5 | 97.5-112 | 1 | 130-149 | 1.5 |
| 7.5 - 8.4 | 75-84 | 0.5 | 112.5-127 | 1 | 150-169 | 1.5 |
| 8.5 - 9.4 | 85-94 | 1 | 127.5-142 | 1.5 | 170-189 | 1.5 |
| 9.5 - 10.4 | 95-104 | 1 | 142.5-157 | 1.5 | 190-209 | 2 |
| 10.5 - 11.4 | 105-114 | 1 | 157.5-172 | 1.5 | 210-229 | 2 |
| 11.5 - 12.4 | 115-124 | 1 | 172.5-187 | 1.5 | 230-249 | 2.5 |
| 12.5 - 13.4 | 125-134 | 1 | 187.5-202 | 2 | 250-269 | 2.5 |
| 13.5 - 14.4 | 135-144 | 1.5 | 202.5-217 | 2 | 270-289 | 2.5 |
| 14.5 - 15.4 | 145-154 | 1.5 | 217.5-232 | 2 | 290-309 | 3 |
| 15.5 -16.4 | 155-164 | 1.5 | 232.5-247 | 2.5 | 310-329 | 3 |
| 16.5 - 17.4 | 165-174 | 1.5 | 247.5-262 | 2.5 | 330-349 | 3.5 |
| 17.5 - 18.4 | 175-184 | 1.5 | 262.5-277 | 2.5 | 350-369 | 3.5 |
| 18.5 - 19.4 | 185-194 | 2 | 277.5-292 | 3 | 370-389 | 3.5 |
| 19.5 - 20.4 | 195-204 | 2 | 292.5-307 | 3 | 390-409 | 4 |
| 20.5 - 21.4 | 205-214 | 2 | 307.5-322 | 3 | 410-429 | 4 |
| 21.5 - 22.4 | 215-224 | 2 | 322.5-337 | 3 | 430-449 | 4.5 |
| 22.5 - 23.4 | 225-234 | 2 | 337.5-352 | 3.5 | 450-469 | 4.5 |
| 23.5 - 24.4 | 235-244 | 2.5 | 352.5-367 | 3.5 | 470-489 | 4.5 |
| 24.5 - 25.4 | 245-254 | 2.5 | 367.5-382 | 3.5 | 490-509 | 5 |
| 25.5 - 26.4 | 255-264 | 2.5 | 382.5-397 | 4 | 510-529 | 5 |
| 26.5 - 27.4 | 265-274 | 2.5 | 397.5-412 | 4 | 530-549 | 5.5 |
| 27.5 - 28.4 | 275-284 | 2.5 | 412.5-427 | 4 | 550-569 | 5.5 |
| 28.5 - 29.4 | 285-294 | 3 | 427.5-442 | 4.5 | 570-589 | 5.5 |
| 29.5 - 30.4 | 295-304 | 3 | 442.5-457 | 4.5 | 590-609 | 6 |
| 30.5 - 31.4 | 305-314 | 3 | 457.5-472 | 4.5 | 610-629 | 6 |

post-admission at outpatient clinics attached to each centre for evaluation of morbidity and toxicity. Any patient not returning for a study visit will be traced for vital status ascertainment (Table 2).

Blood sampling schedule

Following consent and randomisation, blood samples will be taken for the following investigations: full blood count, urea and electrolytes, lactate, glucose, malaria status (malaria slide), blood culture and other clinically indicated investigations (not required by the study protocol). Urine will be taken as soon as possible after trial enrolment for multi-stick analysis for assessment of cola or red colour urine and additional storage for later analysis of gut barrier function. In accordance with national guidelines, HIV testing will be performed during admission procedures since this is one of the eligibility criteria. Pre- and post-test counselling will be done in accordance with routine practice. At admission, a venous blood sample will be collected into Heparin and EDTA tubes and stored for subsequent cytokine and biomarker assays, parasitological (*P. falciparum* HRP2), genetic studies (including sickle cell and glucose-6-phosphatase deficiency status) and immune activation studies (transcriptome

and cellular assays). For the latter, red and white cell pellets will be prepared and stored. Further blood samples will be taken at 72 hours, seven days and 28 days (for biomarker assays and immune activation studies); and at day seven for repeat blood culture (see Table 3). Changes in inflammatory markers (including CRP and procalcitonin, PCT) will be measured retrospectively at 72 hours and day seven and microbiology cure measured at day seven (from blood cultures and using non-culture based molecular diagnostics on stored blood).

Clinical management and monitoring

All trial patients will receive standard of care including (intravenous or oral) anti-malarial drugs following national guidelines, based on WHO syndromic patient management²⁹. We will collect data on all administered drugs. Antipyretics, anticonvulsants and treatment for hypoglycaemia will be administered according to nationally agreed protocols. If required, maintenance fluids will be run at 3-4 ml/kg per hour irrespective of age until the child can drink and retain oral fluids. As the trial is designed to target the use of 'appropriate' antimicrobial treatments, clinicians will be free to prescribe antibiotics other than cephalosporins, quinolones or macrolides on admission

Table 2. Schedule of clinical assessments and laboratory investigations.

| Procedure | Rand* | 0m | 30m | 60m | 90m | 2hr | 4hr | 8hr | 24hr | 48hr | Daily | Disc* |
|--------------------------------------|-------|----|-----|-----|-----|-----|-----|-----|------|------|-------|-------|
| Source documents | X | X | X | X | X | X | X | X | X | X | X | X |
| Clinical notes (doctor) [§] | X | X | X | X | X | X | X | X | X | X | X | X |
| Bedside observations (nurse) | X | X | X | X | X | X | X | X | X | X | X | |
| Haemoglobin (Hb) | X | | | | | | | X | X | X | | |
| Lactate | X | | | | | | | X | X | | | |
| Glucose | X | | | | | X | | X | X | | | |
| Prescription chart | X | | | | | | | | X | X | X | X |
| Anthropometry | X | | | | | | | | | | | X |
| Case report form | X | X | X | X | X | X | X | X | X | X | | X |
| Diagnosis [‡] | X | | | | | | | | | | | X |
| Drugs received | | | | | | | | | X | X | | X |
| Transfusion and iv fluids charts | | | X | X | | X | X | X | X | X | | X |
| Locator details | X | | | | | | | | | | | X |
| Investigations [§] | X | | | | | X | | X | X | X | X | |
| Serious adverse events | | X | X | X | X | X | X | X | X | X | X | X |
| Discharge medication | | | | | | | | | | | | X |

* Rand: At randomisation; Disc: On Discharge from hospital

§ Additional reviews by doctors and nurses will be conducted and recorded, where clinically indicated.

§ Laboratory tests and bedside tests including glucose and lactate at time points shown; plus any additional investigations as clinically required eg chest-Xray

‡ Working diagnosis at admission and final diagnosis at discharge.

Table 3. Detailed laboratory investigation schedule.

| Day from recruitment | D0 | D1 | D3 | D7 | D28 |
|---|----------------|---------------|---------------|--------------|-------------|
| Blood culture | 3 ml | | | 3 ml (cases) | |
| PK studies (cases only) | 2 x 0.25 ml | | | 1 x 0.25 ml | |
| Whole blood (Endotoxin) | 1.5 ml | | 1.5 ml | 1.5 ml | |
| Whole blood EDTA (genetics) | 1 ml | | | | |
| Whole blood (transcriptomics, CRP, procalcitonin, calprotectin, gut barrier function) | 4.5 ml | | 2 ml | 2 ml | 4.5 ml |
| Total blood volume research | 10.4 ml | 0.5 ml | 3.5 ml | 7 ml | 5 ml |
| Urine | x | x | x | | |

PK, pharmacokinetics; CRP, C-reactive protein.

day two based on the child's clinical condition and according to country guidelines. On day three (or earlier if results available) clinicians will be permitted to prescribe broad-spectrum antimicrobials guided by the admission blood culture results (species and/or susceptibility). The Uganda severe malaria guidelines give no specific guidance on the use of antibiotics in severe malaria. Children or their carers will be provided with an appropriate supply of azithromycin drugs if discharged before day five.

The clinical coordinator is responsible for ensuring the discharge check-list is complete and for chasing up inpatient notes at discharge. Any relevant information, especially with regard to date of discharge, serious adverse events (SAEs), treatments, blood transfusions, use of intravenous fluids, oxygen or non-routine treatments or investigations, will be recorded. Children will be assessed on day seven, day 28 and day 90 following recruitment. The parent/guardian will receive a follow up invitation on a card. A symptom checklist and targeted physical examination will be performed at each clinic visit post-discharge. Medical history since last visit including hospital re-admissions, transfusions and grade three or four adverse events related to the antibiotic interventions including severity and likely relationship of any adverse events will be documented by a doctor. Any child lost to follow-up before 90 days will be traced for vital status. In order to minimise losses to follow-up, locator data (maps and identifiable landmark) and mobile phone numbers will be taken on discharge and verified at every review. During the 90 day study period attempts will be made to contact the patient via phone (if available) and to follow-up with home visits, if clinic visits are not attended. In the statistical analysis, a patient will be regarded as 'lost to follow-up' if they were not seen in clinic at the day 90 visit and were not known to have died.

Trial products, storage and accountability

The product to be tested in the trial is azithromycin 100 mg dispersible tablets, which are a commercial product and were obtained for the trial as a donation from Cipla Pharmaceuticals, Mumbai, India. Azithromycin is approved for use in

children in Uganda where the trial will take place. Cipla Ltd is fully GMP compliant and has provided full certificates for the manufacture of these products. Azithromycin will be stored at room temperature and not exceeding 30°C (86°F). It will be stored in these conditions for three years as packaged. The trial coordinator at the site will maintain accountability logs for the antibiotic intervention (standard and interventional). These will be kept securely until verified by the external monitor's visit.

Sub-studies

PKPD study

For PK analysis, model-based sampling strategies will enable the description of both intra- and inter-patient variability. A maximum of 3x 0.2ml samples will be taken from each subject on two occasions between day one to five around meaningful time points to describe the PK throughout a dosing interval plus one sample at follow up on day seven to determine the elimination of azithromycin after end of treatment (a total of seven samples per patient). In the first year we will develop highly sensitive bioanalytical assays using ultra performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS) for determination of azithromycin in stored micro-volumes of plasma (analysis performed at Radboud University, Nijmegen).

Initially a population PK model will be developed for azithromycin and will investigate possible covariates for its PK. This will be followed by an investigation of the relationship between plasma PK and PD using the developed PK model, known MIC-values since the area under the curve (AUC):MIC ratio is the pharmacodynamic driver for azithromycin^{16,30} and the treatment outcomes (changes in CRP at day three and microbiologic cure and/or mortality at day seven). Based on Monte Carlo simulations, we expect that all dose groups should reach the population reference target (adult) AUC_{24h} of at least 3.4 h*mg/L²⁴, although there are no data on absorption in severe malaria, which is characterised by impaired gut function²⁵, hence the need for this pilot. The different doses in 105 children provides variability in exposure so that we identify whether all doses are in the flat part of the exposure-response curve, in

which case the lowest dose will be chosen. Other secondary endpoints include mortality at 48 hours, length of hospital stay (days), re-hospitalisation and other adverse events. Quality-control of stored bacterial isolates, non-culture (molecular) assessment of bacterial infection including the determination of MIC to inform PKPD studies will be batch-processed at KWTRP, Kenya.

Biomarker and gut barrier function

In 105 trial participants and 50 children with controls (severe malaria without Teule criteria) we plan to investigate from admission samples the utility of a range of potential biomarkers including CRP, PCT^{31,32} and endotoxin²⁵, to identify whether any of the above markers, alone or in combination, can predict which at-risk children with severe malaria have bacterial co-infections to improve the sensitivity of clinical/laboratory criteria and enable antimicrobial therapy to be further targeted. We will investigate associations between pathological concentrations of these markers and clinical, parasitological and microbiological data in cases (meeting Teule criteria) and controls (not meeting Teule criteria) to test their accuracy for stratification in the main trial. The samples will also allow us to analyse markers of gut barrier dysfunction – a requisite for bacteraemia (intestinal fatty acid binding protein (I-FABP) and the ileal-bile acid binding protein (I-BABP) and establish whether these can accurately predict children with blood-culture proven bacteraemia alone or in combination with clinical criteria/RDTs. In addition, we will analyse the peripheral blood mononuclear cell transcriptome in a subset of children with and without bacterial co-infection to verify the significant changes in transcriptome we observed in a small pilot study of children with malaria and bacterial co-infection compared to children with malaria alone and to confirm observed changes on the cellular level in a second set of children³³. We will investigate whether changes in gene expression profile can be translated into rapid and affordable biological tests predicting children with bacterial co-infection with high specificity and sensitivity. This later analysis is subject to additional funding.

Trial outcome measures

Primary outcomes

- Change in CRP, a putative marker of sepsis at 72 hours (continuous) and microbiological cure (seven-day) (binary), alone and as a composite with seven-day survival.
- The changes in CRP between day 0 and day 3 as the main endpoint for the PKPD studies.

Secondary outcomes

The secondary outcome measures are:

- Mortality at 48-hours and longer-term survival (to day 28 and to day 90).
- Length of hospital stay (days)
- Re-admission to hospital by 90 days
- Adverse events
- The population PK of azithromycin and their relation (combined with pathogen susceptibility) with treatment outcome (PD).

SAEs and interim analyses

SAEs will be reviewed immediately by a designated physician (SAE reviewer) and reported to the appropriate ethics and regulatory committees within one week. The Chief Investigator will inform the Trial Steering Committee (TSC) and Data Monitoring Committee (DMC) for review on a regular basis (as deemed necessary).

DMC

An independent DMC (see composition at the end of the protocol) will review data on enrolment, safety, adherence to the trial protocol and efficacy at regular intervals and in strict confidence. The terms are covered in the DMC charter, signed by the chair and trial statistician. There are no fixed 'stopping rules'. The DMC will receive and review information on the progress and accruing data of the trial and provide advice on the conduct of the trial to the TSC. The DMC would inform the Chair of the TSC if, in their view the results are likely to convince a broad range of clinicians, including those supporting the trial and the general clinical community, that, on balance, one trial arm is clearly indicated or contraindicated for all participants or a particular category of participants. The DMC is comprised of a chair and two other independent members. None declared conflicts of interest.

Trial monitoring

The Mbale site will use a web enabled trial database and will be responsible for data entry and local trial management. The site will retain the original case report forms (CRFs). Data stored on the database will be checked for missing or unusual values (range checks) and checked for consistency within participants over time. If any such problems are identified, the site will be contacted and asked to verify or correct the entry. Changes will be made on the original CRF and entered into the database at the site. Kilifi Clinical Trial Facility will also send reminders for any overdue and/or missing data with the regular inconsistency reports of errors.

This trial will be monitored according to a monitoring plan which will set out the frequency of visits, the degree of source document verification against the CRFs and the requirements for triggered on-site monitoring visits. This plan will also detail the procedures for review and sign-off. The monitoring will adhere to the principles of ICH GCP.

The site initiation visits will include training in the trial procedures, as well as practical training in administration of trial interventions, reporting guidelines for adverse events of study interventions as well as other trial procedures. All staff at sites involved in the trial will receive formal training in GCP through a dedicated training programme during site initiation visit and will also be required to complete an on-line course.

The Clinical Trial Facility in Kilifi oversees standards and quality of all trials conducted through the KWTP and through its monitoring systems and standard operating procedures are organised to ensure that all sites can be monitored with equal independence and rigor. All monitors will be appropriately qualified and trained.

At each monitoring visit the monitors will:

- verify completeness of Trial Master File
- confirm adherence to protocol
- review eligibility verification and consent procedures
- look for missed clinical event reporting
- verify completeness, consistency and accuracy of data being entered on CRFs
- evaluate drug accountability
- provide additional training as needed

The monitors will require access to all patient medical records including, but not limited to, laboratory test results and prescriptions. The investigator (or delegated deputy) should work with the monitor to ensure that any problems detected are resolved.

Data management

All clinical and laboratory data will be recorded in the CRF and stored with a unique serial number identifier. Data will be entered (double data entry) onto [OpenClinica](#). All data will be regularly backed up and backup copies stored both on and off site. Paper records will be archived in locked cabinets. These cabinets will have limited access with prior authorisation (by the site principal investigator). All data will be partially anonymised prior to presentation or publication of any results. Study participants will be identified by a unique subject identification number but patient identifiable information will not be recorded on the study database in compliance with GCP requirements. The data will be examined for inconsistencies during the trial by the statistician and fed back to study sites for corrections following GCP procedures.

Confidentiality

All clinical data will be held confidentially, and personal identifiers will be removed before analysis of the data and presentation of the results.

Data sharing

After completion of the study, requests for data access from researchers outside the study team will be considered by the trial management team and clinical trials unit (Data Governance Committee), and where indicated, requestors will be asked to develop scientific protocols for approval of secondary analyses. The potential to share data will be included in the participant Information and Consent Form (see extended data section)³⁴.

Statistical analysis

The primary analysis for the trial will describe baseline parameters (stratified by study arm) and compare primary and secondary end points by trial arm. The primary analysis will be by intention to treat and secondary analysis will include those treated per protocol (i.e., receiving five days of azithromycin).

The co-primary outcomes are change in CRP (which will be analysed using normal linear regression adjusting for baseline,

using appropriate transformations) and microbiological cure (seven day) alone and as a composite with seven-day survival (which will be analysed using logistic regression and exact tests as a binary outcome). Analysis of adverse events and re-admission will use time-to-event methods through day 90 counting in-hospital death as a competing risk. Changes in CRP and other inflammatory markers will be analysed using normal linear regression (potentially on log-transformed data), using generalised estimating equations to jointly model changes at 72 hours and day-seven. Adverse events will also be summarised by body system.

Ethics statement

Ethical approval has been obtained Mbale Regional Hospital Research Ethics committee (MRRH_REC 095/2017) and from Imperial College Research Ethics Committee (17IC3965), the sponsor of the study. The trial was registered on ISRCTN (ISRCTN49726849) on 27th October 2017 and updated on 12th August 2020 (detailing delay in start of trial and new start date).

Safety

The randomised trial will be conducted in children who are most likely to benefit from the treatment. We will minimise the risks of cannula insertion and phlebotomy by pretrial training in phlebotomy technique and regular cannula site inspection which is included in a SOP. We have calculated that no more than 1ml/kg of blood will be drawn for research purposes at any one time.

Benefits

Children with severe malaria often develop complications such as convulsions, severe anaemia and hypoglycaemia which through close clinical monitoring will be identified at the earliest opportunity and appropriate therapy initiated. Mbale Regional Referral Hospital trial has considerable experience with managing severe malaria and this will serve to minimise the risks to the patients in the trial. Pretrial training of the dedicated study team will include specific training on general management of severe malaria and its complications. A manual of operations will provide clear management guidelines as well as the details of trial conduct and procedures. Children enrolled in the trial will therefore receive a higher quality of care than those managed routinely.

Plans for dissemination of the study outcomes

Public engagement

Results from this trial will be disseminated locally through community meetings and national meetings with the wider healthcare professional community. These systems have been developed for dissemination of MRC FEAST and TRACT trial results and will be adapted to dissemination for the TABS PKPD trial.

National and international policymakers

The site principal investigator has discussed the study with Ministry of Health staff. When the results are available, we will provide a summary briefing highlighting the trial results and what then next steps will be. Whilst the current study will go some way towards addressing whether azithromycin could be

used as an adjunctive treatment in severe malaria a future trial should include a pragmatic design to ensure results are applicable to health services in Africa. The approach we propose may also have utility for syndromic management of other conditions, especially those whose clinical features overlap with severe malaria and in areas where microbiological diagnostic facilities are non-existent.

Discussion

Severe malaria remains a common cause of paediatric admission in many countries in Africa. Children who have bacterial co-infection are at high risk of poor outcome. Establishing which children with malaria are at greatest risk of bacteraemia is critical to pragmatically inform a policy for targeted antibiotic therapy that could substantially reduce malaria-associated mortality while minimising the risks of excess antibiotic prescribing. Short-course empiric therapy with early termination guided by culture results (to prevent development of resistance³⁵) is commonly practiced in high-income countries. However, poor microbiology services and overloaded health systems mean that this approach is not feasible in much of Africa and a trial designed around it would not be generalisable. Thus, in many parts of Africa antibiotic prescribing in children with severe malaria is highly variable across hospitals, with most physicians essentially using antibiotics “blind”, and thus are unable to follow WHO guidelines recommending stopping broad-spectrum antibiotics when bacterial infection has been ruled out. A more pragmatic approach would be to use a standard short-course of a moderately broad-spectrum antibiotic that is not already recommended for empiric use in a large number of other conditions with the potential for improving both early and post-discharge mortality. Relevant to a future trial and to current guidelines, is that many hospitals in Africa lack microbiological culture facilities, meaning best practice is not obvious given the clear threat posed by antimicrobial resistance^{36,37}. To address this within the context of this study and to inform a future trial, we aim to investigate potential approaches (that may be generalizable in future) to targeting antibiotics where microbiological facilities are not present or reliable.

We favoured investigating azithromycin since one study found that almost 50% of bacterial isolates were resistant to the antibiotics most commonly recommended for empirical use¹¹. For NTS specifically, the efficacy of gentamicin is doubtful and susceptibility testing unreliable due to its intracellular nature^{17,38}. Third generation cephalosporins (e.g. ceftriaxone) are the most widely used antimicrobials but resistance is becoming widespread. Moreover, few children will receive an ‘adequate’ therapeutic dose of cephalosporins, since NTS, the commonest cause of bacterial co-infection, requires ~seven days parenteral therapy thus requiring prolonged hospital stay (median four-five days) with economic implications. Further, adding a major new indication for third generation cephalosporins (severe malaria) risks substantially expanding their use, with downstream threats of AMR to a second-line antibiotic currently recommended for other common childhood diseases. Newer antimicrobials,

apart from financial considerations, have similar concerns that over-use could lead to resistance.

We therefore plan to study azithromycin because of its favourable microbiological spectrum, its inherent antimalarial and immunomodulatory properties and dosing and safety profile. Its long half-life is also likely to protect children at increased risk of NTS bacteraemia during the month following a malaria episode. At present pharmacological data are lacking on the correct dosage of oral azithromycin for treatment of bacterial co-infection in severe malaria in African children. The TABS trial will therefore conduct a Phase III trial comparing three doses of azithromycin: 10, 15 and 20 mg/kg (prescribed for feasibility by weight-bands) spanning the lowest to highest mg/kg doses demonstrated to be equally effective as parenteral treatment for other salmonellae infection. Treatment will be given over five days in children with severe malaria at highest risk of bacterial co-infection (meeting Teule criteria) in order to generate relevant PK data by sparse sampling during dosing intervals. The goal is to determine, via population PK modelling, the optimal azithromycin dose in severe malaria, and investigate associations between azithromycin exposure and potential mechanisms PKPD using change in CRP, a putative marker of sepsis at 72 hours (continuous) and microbiological cure (seven-day) (binary), alone and as a composite with seven-day survival, while providing preliminary data on longer-term survival (to day 90). We will also evaluate whether a combination of clinical, point-of-care diagnostic tests, and/or biomarkers can accurately identify the sub-group of severe malaria with culture-proven bacteraemia by comparison with a control cohort of children hospitalized with severe malaria but not meeting Teule criteria, at low risk of bacterial co-infection.

A future Phase III trial may therefore consider two strata: first comparing a pharmacologically-informed dosage of oral azithromycin to standard-of-care (largely third generation cephalosporins) in children at highest risk of bacterial co-infection and second comparing standard of care versus no antibiotics in children with severe malaria but minimal risk of bacterial co-infection to establish whether a policy for targeted antibiotic therapy could substantially reduce malaria-associated mortality while minimising the risks of excess antibiotic prescribing. Risk of co-infection could be determined by Teule criteria¹¹, but would also be informed by this pilot trial. The primary outcome would be mortality at either day seven, day 28 or day 90 mortality which is also be informed by this pilot trial (other timepoints would be secondary outcomes). Other secondary outcomes include mortality at 48 hours, length of hospital stay (days); subsequent hospital readmission; adverse events, faecal changes in antimicrobial resistance³⁴ and cost-effectiveness.

Trial status

Trial enrolment started in January 2021. The delayed start of recruitment was due to the requirement for CIPLA to donate the trial drug which was mandated by the National Drug Authority (NDA), Uganda. Although we received support from CIPLA (2019) and the relevant approvals for importing the

drug for the trial was then secured from NDA there was significant delays to importing the dispersible azithromycin for the trial and starting the trial due to the COVID epidemic. The trial completed recruitment on 4th October 2021 and follow up on 4th January 2022. The clinical trial data and PKPD are currently being analysed.

Protocol version changes

Version 1.0 was the original protocol submitted for ethical approval to ICREC version 1.1 was given full approval on 11th November 2017 following MRRH approval (27th October 2017) of the revised version 1.0 Protocol (version 1.2: dated 9th October 2018 was approved by ICREC and MRRH REC following minor wording changes as a result of regulatory review/approval.

Roles and responsibilities

Role of study sponsor and funders

The sponsor and funder played no role in in study design and will play no role in data collection, trial management, analysis and interpretation of data and manuscript preparation the decision to submit the report for publication.

Trial Management Group

Kathryn Maitland, Peter Olupot-Olupot, Hellen Mnjalla, Diana Gibb Elizabeth C George and Roisin Connon

Trial Steering Committee

Professor Elizabeth Molyneux, OBE (Chairman): College of Medicine, Blantyre Malawi; Dr Jane Crawley: University of Oxford; Dr Irene Lubega: Department of Paediatrics Makerere University College of Health Sciences, Uganda.

Data Monitoring Committee

Prof. Timothy Peto (Chair): University of Oxford; Dr Jennifer Thompson (Trial Statistician): London School of Hygiene and Tropical Medicine; and Professor Philippa Musoka: Makerere University College of Health Sciences, Uganda.

Sponsor

Imperial College London is the main research Sponsor for this study. For further information regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at:

Joint Research Office, Room 221b, Medical School Building, St Mary's Campus, Norfolk Place, London, W2 1PG. Telephone: +44 (0) 020 7594 1872.

Data availability

Underlying data

No underlying data are associated with this article.

Extended data

Imperial College Research Data Repository: TABS extended data. <https://doi.org/10.14469/hpc/8312>³⁴.

Reporting guidelines

Imperial College Research Data Repository: SPIRIT checklist for "Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial". <https://doi.org/10.14469/hpc/8311>.

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

The study group would like to thank the children and families who have participated in the trial to date. We would also like to thank the clinical, nursing, fieldworker, laboratory and pharmaceutical teams that have supported this study to date across the three sites.

We would like to thank Cipla Pharmaceuticals, Mumbai, India for the donation of azithromycin for the trial.

References

- Noor AM, Kinyoki DK, Munda CW, *et al.*: **The changing risk of *Plasmodium falciparum* malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity.** *Lancet.* 2014; **383**(9930): 1739–1747. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Roca-Feltre A, Carneiro I, Armstrong Schellenberg JRM: **Estimates of the burden of malaria morbidity in Africa in children under the age of 5 years.** *Trop Med Int Health.* 2008; **13**(6): 771–783. [PubMed Abstract](#) | [Publisher Full Text](#)
- Okiro EA, Bitira D, Mbabazi G, *et al.*: **Increasing malaria hospital admissions in Uganda between 1999 and 2009.** *BMC Med.* 2011; **9**: 37. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Dondorp AM, Fanello CI, Hendriksen ICE, *et al.*: **Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.** *Lancet.* 2010; **376**(9753): 1647–1657. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- White NJ, Turner GDH, Day NPJ, *et al.*: **Lethal malaria: Marchiafava and Bignami were right.** *J Infect Dis.* 2013; **208**(2): 192–198. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Maitland K: **Management of severe paediatric malaria in resource-limited settings.** *BMC Med.* 2015; **13**(1): 42. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Olupot-Olupot P, Engoru C, Uyoga S, *et al.*: **High frequency of blackwater fever among children presenting to hospital with severe febrile illnesses in Eastern Uganda.** *Lancet Global Health.* 2015; under review.
- Scott JAG, Berkley JA, Mwangi I, *et al.*: **Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study.** *Lancet.* 2011; **378**(9799): 1316–1323. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Church J, Maitland K: **Invasive bacterial co-infection in African children with *Plasmodium falciparum* malaria: a systematic review.** *BMC Med.* 2014; **12**: 31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- WHO Guidelines Approved by the Guidelines Review Committee: **Guidelines**

- for the treatment of malaria. 3rd edition. In., 3rd edn. Geneva: World Health Organization; 2015.
[PubMed Abstract](#)
11. Nadjm B, Amos B, Mtove G, *et al.*: **WHO guidelines for antimicrobial treatment in children admitted to hospital in an area of intense *Plasmodium falciparum* transmission: prospective study.** *BMJ*. 2010; **340**: c1350.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 12. Lunguya O, Lejon V, Phoba MF, *et al.*: **Antimicrobial resistance in invasive non-typhoid *Salmonella* from the Democratic Republic of the Congo: emergence of decreased fluoroquinolone susceptibility and extended-spectrum beta lactamases.** *PLoS Negl Trop Dis*. 2013; **7**(3): e2103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 13. Crump JA, Sjölund-Karlsson M, Gordon MA, *et al.*: **Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive *Salmonella* Infections.** *Clin Microbiol Rev*. 2015; **28**(4): 901–937.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. de Lastours V, Cambau E, Guillard T, *et al.*: **Diversity of individual dynamic patterns of emergence of resistance to quinolones in *Escherichia coli* from the fecal flora of healthy volunteers exposed to ciprofloxacin.** *J Infect Dis*. 2012; **206**(9): 1399–1406.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Gurnee EA, Ndao IM, Johnson JR, *et al.*: **Gut Colonization of Healthy Children and Their Mothers With Pathogenic Ciprofloxacin-Resistant *Escherichia coli*.** *J Infect Dis*. 2015; **212**(12): 1862–1868.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Girard D, Finegan SM, Dunne MW, *et al.*: **Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.** *J Antimicrob Chemother*. 2005; **56**(2): 365–371.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Lode H: **The pharmacokinetics of azithromycin and their clinical significance.** *Eur J Clin Microbiol Infect Dis*. 1991; **10**(10): 807–812.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Giamarellos-Bourboulis EJ: **Immunomodulatory therapies for sepsis: unexpected effects with macrolides.** *Int J Antimicrob Agents*. 2008; **32** Suppl 1: S39–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Noeld H, Krudsood S, Leowattana W, *et al.*: **In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.** *Antimicrob Agents Chemother*. 2007; **51**(2): 651–656.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Kremsner PG, Adegnikaa AA, Hounkpatin AB, *et al.*: **Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial.** *PLoS Med*. 2016; **13**(1): e1001938.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Maitland K, Kiguli S, Olupot-Olupot P, *et al.*: **Immediate Transfusion in African Children with Uncomplicated Severe Anemia.** *N Engl J Med*. 2019; **381**(5): 407–419.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Maitland K, Kiguli S, Opoka RO, *et al.*: **Mortality after fluid bolus in African children with severe infection.** *N Engl J Med*. 2011; **364**(26): 2483–2495.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Mpoya A, Kiguli S, Olupot-Olupot P, *et al.*: **Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial.** *Trials*. 2015; **16**(1): 593.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Matzneller P, Krasniqi S, Kinzig M, *et al.*: **Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.** *Antimicrob Agents Chemother*. 2013; **57**(4): 1736–1742.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Olupot-Olupot P, Urban BC, Jemutai J, *et al.*: **Endotoxaemia is common in children with *Plasmodium falciparum* malaria.** *BMC Infect Dis*. 2013; **13**: 117.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Maitland K, Molyneux S, Boga M, *et al.*: **Use of deferred consent for severely ill children in a multi-centre phase III trial.** *Trials*. 2011; **12**: 90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Zhao Q, Tensfeldt TG, Chandra R, *et al.*: **Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets.** *Malar J*. 2014; **13**: 36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Sykes A, Hendriksen I, Mtove G, *et al.*: **Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial.** *Clin Infect Dis*. 2009; **49**(8): 1195–1201.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. **Hospital Care for Children: guidelines for the management of common illnesses with limited resources.** In: Geneva, Switzerland: World Health Organization; 2005.
[Reference Source](#)
 30. Muto C, Liu P, Chiba K, *et al.*: **Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in artemesunate patients with common respiratory tract infectious disease.** *J Antimicrob Chemother*. 2011; **66**(1): 165–174.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. van den Bruel A, Thompson MJ, Haj-Hassan T, *et al.*: **Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review.** *BMJ*. 2011; **342**: d3082.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Simon L, Gauvin F, Amre DK, *et al.*: **Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.** *Clin Infect Dis*. 2004; **39**(2): 206–217.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Boldt ABW, van Tong H, Grobusch MP, *et al.*: **The blood transcriptome of childhood malaria.** *EBioMedicine*. 2019; **40**: 614–625.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Coles CL, Mabula K, Seidman JC, *et al.*: **Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant *Streptococcus pneumoniae* carriage in young children 6 months after treatment.** *Clin Infect Dis*. 2013; **56**(11): 1519–1526.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Dellinger RP, Levy MM, Carlet JM, *et al.*: **Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.** *Crit Care Med*. 2008; **36**(1): 296–327.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Färnert A, Gwer S, Berkley JA: **Clinical considerations for antibiotic choices in the treatment of severe malaria.** *Trends Parasitol*. 2010; **26**(10): 465–466.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Maitland K: **Antimicrobials in children admitted to hospital in malaria endemic areas.** *BMJ*. 2010; **340**: c1818.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Graham SM, English M: **Non-typhoidal salmonellae: a management challenge for children with community-acquired invasive disease in tropical African countries.** *Lancet*. 2009; **373**(9659): 267–269.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ?

Version 1

Reviewer Report 07 February 2022

<https://doi.org/10.21956/wellcomeopenres.18730.r48482>

© 2022 Rogerson S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Stephen J. Rogerson

Department of Infectious Disease, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Vic, Australia

Dr Olupot-Olupot and colleagues present a protocol for a trial that recently commenced recruitment in Uganda, comparing different doses of oral azithromycin as adjunctive treatment for children with severe malaria. Although all doses would be expected to be effective if used parenterally for the commonest pathogen, non-typhoidal salmonellae, impaired gut function might affect drug absorption, justifying the range of doses under study.

Given this appears primarily to be a dose-finding study for a proposed definitive study, some of the hypotheses, aims and the primary outcomes do not seem to be particularly aligned with this, focusing instead on biomarker and bacterial sepsis endpoints, which the sample size is unlikely to be powered to address effectively. With 35 children per group, and a possible bacterial sepsis rate of 20% only a handful of children in each group are likely to have sepsis. By contrast, the justification for the pharmacokinetic aspects of the study is strong.

The trial was originally registered in 2017, but logistical delays including COVID-related disruptions led to delayed initiation to January 2021.

The descriptions of the trial procedures (with a couple of exceptions, noted below) are mostly clear, but there are some points for clarification.

Major comments:

1. The co-primary endpoint of “change in CRP at 72 hours” needs better explanation. Malaria itself elevates CRP, so what is the evidence to support using this as a discriminating factor between malaria and malaria+ bacteraemia? There is no discussion to justify this.
2. Control group: 50 children are to be recruited and not treated with azithromycin. At different points these are described as “those hospitalised with severe malaria but not meeting Teule criteria” (which includes severe anaemia, respiratory distress, and

prostration, including cerebral malaria, as well as HIV infection); and elsewhere as “non-severe malaria”, Figure 1 and “treatment allocation”, Page 7. Given most severe malaria in Uganda is due to severe anaemia, cerebral malaria and/or respiratory distress and few children who do not meet the Teule criteria but do have severe malaria may be expected, please clarify which children will be in the “control” group.

3. On page 4 the authors claim that the azithromycin half life is such that it is likely to offer protection from bacteraemia for a month. My reading of the literature is that drug concentrations in target tissues are expected to be above MICs for ~10 days (Lode *et al.*, J Antimicrob Chemother 1996).¹
4. Given dosing is weight based, are there upper and lower weight limits as well as age limits? If so please provide these.
5. Treatment: will the children receive artemether-lumefantrine after they complete parenteral artesunate?
6. Number of blood samples for PK studies: to my reading it was not clear whether this is 4 samples per child (Figure 1)? Or “a total of 7 samples per child” (PKPD substudy, page 10)?
7. Under “statistical analysis” there is no discussion of analysis and interpretation of the PK data which to my mind is the main justification for the study.
8. In the discussion, the authors state “Establishing which children with malaria are at greatest risk of bacteraemia is critical to pragmatically inform a policy for targeted antibiotic therapy that could substantially reduce malaria-associated mortality while minimising the risks of excess antibiotic prescribing.” Whilst true, the present study does not address this question, rather it gives all children in established high risk groups treatment.

Minor comments:

1. The methods section of the abstract is hard to follow, particularly the sentence which reads “and investigate azithromycin exposure to change in C-reactive protein, a putative marker of sepsis at 72 hours, and microbiological cure (seven-day) alone and as a composite with seven-day survival.”
2. The list of abbreviations is quite incomplete.
3. In the Introduction, there is a very long sentence that needs revision, starting with “Even when with the best (evidence-based)...”
4. There is no mention of molecular diagnosis of malaria. Will this be performed?
5. Is the LC/MS set up now in Nijmegen? There are published methods for this, using small volumes of plasma.
6. Under “Trial monitoring” the first sentence is unclear.. It reads: “The Mbale site on to a web enabled trial database will be responsible for its own data entry and local trial management

References

1. Lode H, Borner K, Koeppe P, Schaberg T: Azithromycin--review of key chemical, pharmacokinetic and microbiological features. *J Antimicrob Chemother.* 1996; **37 Suppl C**: 1-8 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the rationale for, and objectives of, the study clearly described?

Partly

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Malaria in pregnancy and childhood. Pathogenesis and immunity. Collaborations with clinical pharmacologists but o specific expertise.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
